2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1571

RNA Sequencing Detection of Gene Dysregulation in Epithelial Cells Sorted from Salivary Gland Tissue Reveals Interesting Pathways Involved in Primary Sjögren’s Syndrome Pathophysiology
Abstract Number: 1822

RNA-Sequencing of Mouse and Human Synovial Fibroblasts Reveals Fibroblast Subset-Specific Responses to Inflammation
Abstract Number: 129

Rnaseq Analysis of Human Skin in Organ Culture Identifies Collagen 22A1 As a TGF-β Early Response Gene
Abstract Number: 1349

Rnaseq of Peripheral Blood Mononuclear Cells from Juvenile Dermatomyositis, Necrotizing Myopathy and Controls Are an Aid in Diagnosis
Abstract Number: 6

Ro52/Trim21 Influences Follicular B Cell Homeostasis and Immunoglobulin Production
Abstract Number: 1830

Role of BMP2 in Entheseal Bone Formation in Inflammatory Arthritis
Abstract Number: 2968

Role of Choline in Gouty Inflammation
Abstract Number: 2073

Role of miRNA-21-5p As a Potential Biomarker for the Inflammation Pathway in Psoriatic Disease and Response to Methotrexate Treatment
Abstract Number: 1063

Role of Mitochondrial-Bound HK2 in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Abstract Number: 1686

Rule-Based Algorithm Using Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria to Identify Patients with Systemic Lupus Erythematosus (SLE) from Electronic Health Record (EHR) Data
Abstract Number: 1470

Russell Bodies and Serological Status in Rheumatoid Arthritis
Abstract Number: 413

S100A8 & S100A9: Alarmin Mediated Inflammation in Tendinopathy
Abstract Number: 1872

Safety and Efficacy of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus: Results of an Open-Label Phase I Study
Abstract Number: L06

Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards
Abstract Number: 1715

Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].